Abstract A group of 82 adult patients with acute myelogenous leukaemia who had survived in continuous first remission for more than three years was studied. These long-surviving patients were being treated at 12 referral centres in Europe and the USA, and they were compared with other patients with acute myelogenous leukaemia from 10 of these centres. There was no clear difference in the amount of induction chemotherapy or the time taken to achieve remission. Immunotherapy was not found to improve chances of long-term survival. The 82 patients were also compared with a group of 115 patients who had survived in remission for less than three years. There was no appreciable difference in the number of blood or marrow myeloblasts between these two groups at presentation, but the long survivors had significantly higher initial platelet counts and were slightly younger. The long survivors also tended to have a lower total white
Introduction
There have been several studies of long-surviving patients with acute leukaemia,' -but these have been concerned principally with acute lymphoblastic leukaemia. Many of the remissions for acute myelogenous leukaemia have been relatively short,4 though remission rates have improved rapidly and some authors have suggested that as many as 10% of patients with acute myelogenous leukaemia may survive a long time6; a detailed report of 16 long-surviving patients has been published. 7 We studied a group of 82 adults with acute myelogenous leukaemia, all of whom had survived for at least three years in continuous first remission. We compared these patients with two other groups of patients with acute myelogenous leukaemia who survived for less than three years.
Patients and methods
Information was obtained on 82 patients in 12 centres in Europe and the United States (table I) by means of a questionnaire. All had been in continuous complete remission for at least three years and with one exception (aged 12 years) were adults aged years at the time they presented. Details of age, sex, initial blood counts, induction treatment, maintenance treatment, immunotherapy, remission duration, and duration of survival were analysed for all patients. . Possible statistical differences were examined using Student's Bone marrow smears taken at presentation from the long-surviving patients were reviewed to establish the diagnosis and to subdivide the patients into groups according to the classification of leukaemia proposed by the French-American-British (FAB) co-operative group.8 Sixty-one marrows were examined by one of the authors (JAW). The remaining 21 marrows were reviewed at the centres of origin, but one centre did not use the FAB classification.
Results
Leukaemia subtype-Review of bone marrow smears confirmed that the original diagnosis was correct for all 82 patients. Seventy-four of these patients were classified by the FAB system (table II) Comparisons between patients with a long survival and patients with "standard" survival-Comparisons were made between our 82 patients and 115 patients in Cardiff who entered remission after similar induction treatment but survived for less thanthree years. There were no significant differences between the groups for sex, blood blast count, or percentage of marrow blast cells (table III) . The 82 patients with long survival, however, had significantly higher initial platelet counts (p=0 001) and were slightly younger than the Cardiff patients (p --0 009). They also had a slightly lower total white cell count (p =0 02) and a lower granulocyte count (p -0 01). These differences in platelet count, granulocyte count, and total white cell count persisted when the two sets of patients were stratified into similar age groups. 693 survived for more than three years had received more chemotherapy than other patients with acute myelogenous leukaemia we examined details of induction treatment. Sixty-three patients from 10 of the participating centres were in chemotherapy trials and had received treatment which included cytarabine and daunorubicin (or doxorubicin). Courses of induction chemotherapy varied slightly between centres, mainly in the timing and amount of cytarabine given. Nevertheless, it was possible to compare the total amounts of cytarabine and daunorubicin (or doxorubicin) given to the 63 who had survived for more than three years with that given to all patients for each of the 10 centres; no clear difference was seen. We also compared the number of induction treatments received by each long-surviving patient with the Remission duration-Analysis of remission duration and total survival for the 82 patients (table IV) showed that eight patients relapsed after three to four years. Forty patients reached five years in continuous first remission and only two patients relapsed subsequently, one in the sixth year and one after more than six years in continuous remission. None of the 16 patients in complete remission for more than seven years has relapsed. A more detailed examination of the patients who relapsed or died is shown in table V. One patient died from meningeal leukaemia, but there was no other example of meningeal leukaemia in the group of 82 long survivors, 75 of whom had not received any form of central nervous system prophylaxis.
Induction chemotherapy-To decide whether patients who had mean number of treatments given to other patients at the same referral centre to achieve remission (table VI) . Six patients had required three or more additional induction treatments to reach remission, but reexamination of data from these patients did not suggest that their leukaemia differed in any way from that of the others. Most longsurviving patients had not entered remission more quickly (or more slowly) than other patients with acute myelogenous leukaemia treated at the same centre. 
An assessment of the chance of long survival in acute myelogenous leukaemia is important as it may have a direct relation to the chance of eventual cure. Although our series included patients from 12 different centres, an accurate estimate was possible because eight of the centres carried out trials in which patients at the centre received identical induction chemotherapy, and remission patients were then entered into a con- trolled trial of immunotherapy. Many of these trials have been reported elsewhere. In all, 1283 patients were treated, with 558 (43 5%) achieving remission and 56 (4A40%) surviving in complete remission for more than three years. These trials were started as early as 1971 and the mean remission rate of 43-5% would probably be higher with current induction treatments. Although the number of patients surviving for three years would also probably increase, a direct correlation with the remission rate is unlikely because high rates of remission can be offset by relapses after a disappointingly short time.4 5 Although Burchenal' s idea that long-surviving patients with acute lymphoblastic leukaemia differed fundamentally from other patients with acute lymphoblastic leukaemia7 is untenable now that five-year survival rates greater than 50% are commonplace, several poor prognostic features have subsequently been shown9-namely, high initial blood blast cell counts, the presence of a mediastinal mass, and appreciable enlargement of the liver and spleen. With the subsequent subtyping of acute lymphoblastic leukaemia according to cell surface antigens,10 1' additional clinical and prognostic differences in acute lymphoblastic leukaemia emerged. These differences for patients with acute myelogenous leukaemia are not yet clearly evident, but it has been suggested that morphological subtype may be important.12 In particular, acute promyelocytic leukaemia may have a more favourable prognosis than other subtypes.13
Most of our patients had acute myeloblastic leukaemia (M, or M, in the FAB classification) or acute myelomonocytic leukaemia (M4 in the FAB classification). It was not possible to relate closely disease subtype to prognosis, but fewer relapses occurred in the patients with M2 and M4 subtypes than in patients with M1 disease. The importance of this finding is not clear.
Furthermore, we could not show any significant difference in sex, blood blast count, or percentage of marrow blast cells between our 82 long-surviving patients and a group of 115 patients in Cardiff who had entered remission but had had a "standard" survival of less than three years. The long survivors, however, were considerably younger and had significantly higher initial platelet counts. The Medical Research Council have previously reported12 14 that age is the chief determinant of prognosis for patients with acute myelogenous leukaemia both for incidence of remission and for duration of survival. Information from the MRC fifth trial of treatment for acute myelogenous leukaemia showed that the initial platelet count was significantly related to the duration of survival but not to the remission rate.'2 The follow-up was relatively short, however, and the series included only a few patients who had survived for more than two years. Results from other studies show only a marginal relation between age and duration of survival6 16 or no effect at all.9 Most of the few published studies of long survivors in acute myelogenous leukaemia have either not included data on platelet count or have found no relation between initial platelet count and long survival.
There is no obvious explanation for our finding of slightly higher total white cell counts and granulocyte concentrations in the long-surviving patients. The MRC study'2 showed that the white cell count was significantly but not strongly related to prognosis, survival being slightly worse for patients with high counts.
We also examined the amount and duration of induction chemotherapy received by 63 of our patients in whom treatment had included cytarabine and an anthracycline. It was possible to compare each patient's treatment with standard treatment used to achieve remission for all patients at the referral centre. For many of the long-surviving patients the duration and amount of induction chemotherapy had been standard, and analysis of a small group of patients who had required either more chemotherapy courses or a longer treatment interval to achieve remission did not show differences in bone marrow morphology or initial blood counts. These observations confirm that our group of patients did not include patients with subacute or smouldering leukaemia, whose disease might be expected to have a more benign course.
Several This admirable solar shrub is scarce to be paralleled for its virtues. The berries are hot in the third degree, and dry but in the first, being a most admirable counter-poison, and as great a resister of the pestilence, as any growing; they are excellent good against the bitings of venomous beasts, they provoke urine exceedingly, and therefore are very available to dysuries and stranguaries. It is so powerful a remedy against the dropsy, that the very lye made of the ashes of the herb being drank, cures the disease. It provokes the terms, helps the fits of the mother, strengthens the stomach exceedingly, and expels the wind. Indeed there is scarce a better remedy for wind in any part of the body, or the cholic, than the chymical oil drawn from the berries; such country people as know not how to draw the chymical oil, may content themselves by eating ten or a dozen of the ripe berries every morning fasting. They are admirably good for a cough, shortness of breath, and consumption, pains in the belly, ruptures, cramps and convulsions. They give safe and speedy delivery to women with child, they strengthen the brain exceedingly, help the memory, and fortify the sight by strengthening the optic nerves; are excellently good in all sorts of agues; help the gout and sciatica, and strengthen the limbs of the body. The ashes of the wood is a speedy remedy to such as have the scurvy, to rub their gums with. The berries stay all fluxes, help the haemorrhoids or piles, and kill worms in children. A lye made of the ashes of the wood, and the body bathed with it, cures the itch, scabs and leprosy. The berries break the stone, procure appetite when it is lost, and are excellently good for all palsies, and falling-sickness. (Nicholas Culpeper (1616-54) The Complete Herbal,
